# US 2025/0144136 A1 · Fetal macrophage and cell preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144136 A1
- Document ID: US20250144136A1
- Status: Published application
- Kind: A1
- Application number: 18/835,446
- Filed: 2023-02-09
- Published: 2025-05-08
- Earliest claimed: 2022-02-10
- Assignees: Keio University
- Applicants: Keio University
- Inventors: Shigeki SAKAI; Kazuo KISHI
- Web page: https://patentgrep.com/patent/US20250144136A1

## CPC

- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 8/98: of animal origin
- A61K 8/982: {Reproductive organs; Embryos, Eggs}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- C12N 5/06: {Animal cells or tissues; Human cells or tissues (preservation of excised living parts A01N1/10)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A cell population including macrophages that are CD11b positive, F4/80 positive, CD180 positive, and CD9 positive and that are derived from a tissue selected from the group consisting of placenta, umbilical cord, and amnion with a percentage of 75% or more, the cell population having cell viability of 80% or more.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A cellular therapeutic preparation comprising, as an active ingredient,
a cell population as an active ingredient comprising macrophages that are CD11b positive, F4/80 positive, CD180 positive, and CD9 positive and that are derived from a tissue selected from the group consisting of placenta, umbilical cord and amnion as an active ingredient with a percentage of 75% or more, the cell population having cell viability of 80% or more.

### Claim 18 (depends on 17)

The cellular therapeutic preparation according to claim 17, wherein the macrophages are non-adherent cells.

### Claim 19 (depends on 17)

The cellular therapeutic preparation according to claim 17, wherein the macrophages include Hofbauer cells.

### Claim 20 (depends on 17)

The cellular therapeutic preparation according to claim 17, wherein the cellular therapeutic preparation is an injectable preparation.

### Claim 21 (depends on 17)

A method of transplanting cells into a subject, comprising administering a therapeutically effective amount of the cellular therapeutic preparation according to claim 17 to the subject.

### Claim 22 (depends on 17)

A method of treating a disease selected from the group consisting of an inflammatory disease, an immunomodulatory disease, and an autoimmune disease in a subject, comprising administering a therapeutically effective amount of the cellular therapeutic preparation according to claim 17 to the subject.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the inflammatory disease includes inflammatory bowel disease or chronic inflammatory disease.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the immunomodulatory disease includes a graft-versus-host disease, systemic lupus erythematosus, liver cirrhosis, pulmonary fibrosis, atopic dermatitis, or aging.

### Claim 25 (depends on 17)

A method of treating a subject, comprising administering a therapeutically effective amount of the cellular therapeutic preparation according to claim 17 to the subject, wherein the treating include promotion of epithelialization, promotion of angiogenesis, inhibition of scarring, inhibition of thickening of the skin, suppression of wrinkle, healing of wound, or suppression of fibrosis.

### Claim 26

A cellular therapeutic preparation comprising a cell population comprising macrophages that are CD11b positive, F4/80 positive, CD180 positive, and CD9 positive and that are derived from a tissue selected from the group consisting of placenta, umbilical cord and amnion as an active ingredient.

### Claim 27 (depends on 26)

The cellular therapeutic preparation according to claim 26, wherein the macrophages are non-adherent cells.

### Claim 28 (depends on 26)

The cellular therapeutic preparation according to claim 26, wherein the macrophages include Hofbauer cells.

### Claim 29 (depends on 26)

The cellular therapeutic preparation according to claim 26, wherein the cellular therapeutic preparation is an injectable preparation.

### Claim 30 (depends on 26)

A method of transplanting cells into a subject, comprising administering a therapeutically effective amount of the cellular therapeutic preparation according to claim 26 to the subject.

### Claim 31 (depends on 26)

A method of treating a disease selected from the group consisting of an inflammatory disease, an immunomodulatory disease, and an autoimmune disease in a subject, comprising administering a therapeutically effective amount of the cellular therapeutic preparation according to claim 26 to the subject.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the inflammatory disease includes inflammatory bowel disease or chronic inflammatory disease.

### Claim 33 (depends on 31)

The method according to claim 31, wherein the immunomodulatory disease includes a graft-versus-host disease, systemic lupus erythematosus, liver cirrhosis, pulmonary fibrosis, atopic dermatitis, or aging.

### Claim 34 (depends on 31)

A method of treating a subject, comprising administering a therapeutically effective amount of the cellular therapeutic preparation according to claim 31 to the subject, wherein the treating include promotion of epithelialization, promotion of angiogenesis, inhibition of scarring, inhibition of thickening of the skin, suppression of wrinkle, healing of wound, or suppression of fibrosis.

### Claim 35 (depends on 17)

A cosmetic composition comprising the cell population according to claim 17.

### Claim 36 (depends on 26)

A cosmetic composition comprising the cell population according to claim 26.
